Compare

Vsee Health, Inc. vs Omada Health, Inc. vs GeneDx Holdings Corp. vs Pennant Group, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearVsee Health, Inc.
VSEE
Omada Health, Inc.
OMDA
GeneDx Holdings Corp.
WGS
Pennant Group, Inc.
PNTG
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$14.62M$260.21M$427.54M$947.71M
Revenue growth (YoY)+40.3%+53.2%+40.0%+36.3%
Gross margin50.3%65.7%69.7%n/a
Operating margin-65.6%-4.6%-3.1%5.5%
Net margin-100.6%-4.9%-4.9%3.1%
Net income-$14.71M-$12.78M-$21.02M$29.58M
EPS (Diluted)-$0.73-$0.35-$0.73$0.84
Operating cash flow-$3.45M$18.25M$33.28M$48.29M
Free cash flow-$3.48M$16.93M$14.26M$36.26M
Cash & equivalents$5.27M$222.04M$105.00Mn/a
Total assets$22.41M$305.41M$523.71M$968.18M
Total liabilities$16.96M$75.73M$215.53M$593.93M
Shareholders' equity$5.45M$229.68M$308.18M$374.25M
Return on year-end equity-269.8%-5.6%-6.8%7.9%
Shares outstanding33.19M58.43M29.25M34.63M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearVsee Health, Inc.Omada Health, Inc.GeneDx Holdings Corp.Pennant Group, Inc.
Latest$14.62M
Ended 2025-12-31
$260.21M
Ended 2025-12-31
$427.54M
Ended 2025-12-31
$947.71M
Ended 2025-12-31
1 year earlier$10.42M
Ended 2024-12-31
$169.80M
Ended 2024-12-31
$305.45M
Ended 2024-12-31
$695.24M
Ended 2024-12-31
2 years earlier$5.77M
Ended 2023-12-31
$122.78M
Ended 2023-12-31
$202.57M
Ended 2023-12-31
$544.89M
Ended 2023-12-31
3 years earliern/an/a$234.69M
Ended 2022-12-31
$473.24M
Ended 2022-12-31
4 years earliern/an/a$212.19M
Ended 2021-12-31
$439.69M
Ended 2021-12-31